A world class Pharma leader in injectables from INDIA is looking for partners who are interested in technology transfer of biotherapeutic products or Joint venture to develop bio products.

Network Biosystems (NetBio) fuses microelectronics and biotechnology to build bio-nanotech systems that perform rapid DNA sequencing for clinical diagnostics. NetBio intends to create a paradigm shift in the application of DNA sequencing to clinical medicine by enabling the physician to make rapid clinical decisions based on real-time DNA sequence data. NetBio’s DNA analysis platform has been validated by the introduction of Genebench-FX™, a rugged and portable DNA fingerprinting system currently in use for rapid analysis of DNA evidence found at crime scenes. The Company is seeking partnerships with pharmaceutical, biotechnology, and diagnostics companies to develop markets in infectious disease, cancer, and pharmacogenomic profiling.

Colby Pharmaceutical Company (Menlo Park, California) is developing three important new prostate targeted small molecule therapeutic oncology drugs for the treatment of (1.) early non-progressive prostate cancer (PCa), (2.) progressive hormone-dependent as well as hormone-independent PCa, and (3.) advanced metastatic hormone-refractory PCa. The lead drug, for the therapy of progressive PCa, is a novel prostate targeted anti-androgenic anti-oxidant and is scheduled to begin a Phase I/II human clinical trial in 2008. Colby Pharmaceutical Company is seeking a strategic partner.

Stemina Biomarker Discovery has developed proprietary technology to use human embryonic stem cells (hESC), hESC derivative cell types and cancer stem cells as a source of predictive biomarkers for disease diagnostics and preclinical safety evaluation of pharmaceuticals. Stemina's pioneer cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics. As a result, we discover and validate human biomarkers for high throughput diagnostics and drug screening.

SiDMAP is a privately owned start-up biotech company founded in 2004 and incubated at the UCLA School of Medicine's LA BioMed. SIDMAP (Stable isotope dynamic metabolic profiling) is a patented technology that uses tracer-based metabolomics to analyze mutltiple biochemical pathways in one assay. We are based in Los Angeles, CA and service biotech and pharma in North America, Europe, and Asia, better enabling these companies in their drug discovery and development programs through a "systems" approach to biomarker development, mechanism of action studies, drug respositioning, lead optimization, and toxicology studies.

Jivan Biologics Inc. specializes in microarrays for alternate splicing and provides a full catalogue of splice variant arrays to benefit all stages of the drug development pipeline. Available as a service since 2001 and as catalogue products since 2003, Jivan's flagship SpliceExpress™ arrays are the first commercial microarrays for alternate splicing. Drug companies, research hospitals and universities have adopted SpliceExpress™ products as a platform of choice to characterize RNA splicing in disease and normal samples. Jivan is looking to partner with pharmaceutical companies in identifying biomarkers for drug toxicity, dentification/development of cancer biomarkers, and blood biomarkers in psychiatric illnesses. Jivan is currently working with research groups to develop diagnostic markers for cancer. Jivan customers are also applying SpliceExpress™ to cardiovascular disorders, drug treatment, blood-based biomarker discovery, gene knockout studies, time course studies, and dose-response.

Onconome, Inc., founded in 2001, is committed to the discovery, development and commercialization of In Vitro Diagnostics for the early detection of prostate, colorectal, bladder and other forms of cancer. Onconome's innovative and proprietary tests have demonstrated remarkable specificity and sensitivity in large studies at Johns Hopkins University and address the huge unmet need for early cancer detection. Through a close relationship with the Brady Urological Institute at Johns Hopkins University, Onconome is developing new, highly specific and sensitive serum, tissue and urine assays for the early diagnosis of cancer and will assist pharmaceutical companies in their efforts to develop cancer therapies and improve treatment.

Orion Integrated Biosciences Inc. was founded in 2003. Eleven researchers combine breakthroughs on genomics, nanotechnology, and bioinformatics to develop innovative solutions addressing complex infectious diseases posing significant risk to people’s health. Our strategy is to generate profit margins in the following areas: 1) biothreat detection and diagnostics 2) bioinformatics software development for infection biomarker discovery, 3) rational antiviral and attenuated vaccine development, and 4) intellectual property rights licensing of therapeutic targets. At this point, we are looking to scale our operations, raise sufficient capital to form strong partnerships with the large pharmaceutical corporations and distribute our diagnostics technology worldwide.

Kronos Science Laboratory (KSL) is a full-service, quality driven central laboratory and contract research organization specializing in custom assay development, test validation, diagnostic testing services and translational research and development. We provide specialty laboratory services to pharmaceutical companies, biotechnology companies and other organizations engaging in clinical trials and basic research. Our goal is to provide thorough, cost effective laboratory testing and contract research services to our clients as well as to bring the most state of the art technologies from internal research to market. Our areas of expertise are Cardiovascular Disease, Alzheimer’s Disease, Inflammation, Oxidative Stress, Endocrinology and Nutrition.

We are a leader quality control company in Chile accredited ISO 17025. We are interested to be the representatives or create partnerships with core technologies companies with business related to our area operating as the laboratory partner in the region to offer your services.

We have a interested project for the livestock identification and meat traceability market based on eartags with tissue collection and DNA-fingerprinting services. We are creating a global network to carry out and commercialise the project. We are seeking for companies with business related wanting to generate partnerships with us for business expansion and commercialisation. Please ask for our executive summary